# US 2020/0369755 A1 · Antibodies recognizing tau

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369755 A1
- Document ID: US20200369755A1
- Status: Published application
- Kind: A1
- Application number: 16/808,209
- Filed: 2020-03-03
- Published: 2020-11-26
- Earliest claimed: 2019-03-03
- Assignees: Prothena Biosciences Limited
- Applicants: Prothena Biosciences Limited
- Inventors: Tarlochan S. Nijjar; Robin BARBOUR; Philip James DOLAN, III; Yue LIU; Svetlana ALEXANDER; Mark RENZ
- Web page: https://patentgrep.com/patent/US20200369755A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

## Claims

### Claim 1

An isolated antibody specifically binding to human tau, comprising:
a mature heavy chain variable region comprising CDR-H1 comprising SEQ ID NO:8, CDR-H2 comprising SEQ ID NO:9 or SEQ ID NO:149, and CDR-H3 comprising SEQ ID NO:10, wherein the heavy chain variable region is at least 90% identical to SEQ ID NO:18; and
a mature light chain variable region comprising CDR-L1 comprising SEQ ID NO:12, CDR-L2 comprising SEQ ID NO: 150, 151, 153, 156, 158, 159, 160, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173 or 174, and CDR-L3 comprising SEQ ID NO:14, wherein the light chain variable region is at least 90% identical to SEQ ID NO:122.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein at least one of positions H12, H13, H17, H24, H40, H43, H48, H66, H67, H76, H80, H81, and H91 can be occupied by V, K, T, A, R, Q, I, R, A, D, L, Q, and F, respectively, and at least one of positions L2, L12, L15, L37, L39, L45, L60 and L100 can be occupied by V, P, L, Q, R, R, D and Q respectively.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein CDR-L2 comprises SEQ ID NO:150, 151, 163, 167, 168, or 169.

### Claim 4 (depends on 3)

The antibody of claim 3, wherein the heavy chain variable region comprises SEQ ID NO:18 and the light chain variable region comprises SEQ ID NO:110, 121, 122 or 123.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 4)

The antibody of claim 4, wherein the light chain variable region comprises SEQ ID NO:122.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 3)

The antibody of claim 3, wherein the heavy chain variable region comprises SEQ ID NO:146 and the light chain variable region comprises SEQ ID NO:94.

### Claim 11 (depends on 3)

The antibody of claim 3, wherein the heavy chain variable region comprises SEQ ID NO:146 and the light chain variable region comprises SEQ ID NO:122.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The antibody of claim 1 wherein the antibody is a chimeric, veneered, or humanized antibody.

### Claim 14 (depends on 1)

The antibody of claim 1 that is an intact antibody.

### Claim 15 (depends on 1)

The antibody of claim 1 that is a binding fragment.

### Claim 16 (depends on 15)

The antibody of claim 15, wherein the binding fragment is a single-chain antibody, Fab, or Fab′2 fragment.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The antibody of claim 1, wherein the isotype is human IgG1, human IgG2 or human IgG4.

### Claim 19 (depends on 1)

The antibody of claim 1 wherein the mature light chain variable region is fused to a light chain constant region and the mature heavy chain variable region is fused to a heavy chain constant region.

### Claim at position 18

20-21. (canceled)

### Claim 22 (depends on 19)

The antibody of claim 19, wherein the heavy chain constant region has an amino acid sequence of SEQ ID NO: 176 with or without C-terminal lysine.

### Claim 23 (depends on 19)

The antibody of claim 19, wherein the mature heavy chain variable region fused to a heavy chain constant region has an amino acid sequence of SEQ ID NO: 178 with or without C-terminal lysine.

### Claim 24 (depends on 19)

The antibody of claim 19, further comprising a signal peptide fused to the mature heavy and/or light chain variable region.

### Claim 25 (depends on 23)

The antibody of claim 23, wherein the heavy chain has an amino acid sequence of SEQ ID NO:180 with or without C-terminal lysine.

### Claim 26 (depends on 19)

The antibody of claim 19, wherein the light chain constant region has an amino acid sequence of SEQ ID NO:177.

### Claim 27 (depends on 19)

The antibody of claim 19, wherein the mature light chain variable region is fused to a light chain constant region has an amino acid sequence of SEQ ID NO:179.

### Claim 28 (depends on 27)

The antibody of claim 27, wherein the light chain has an amino acid sequence of SEQ ID NO:181.

### Claim 29 (depends on 23)

The antibody of claim 23, wherein the heavy chain has an amino acid sequence of SEQ ID NO:178 with or without C-terminal lysine and the light chain has an amino acid sequence of SEQ ID NO:179.

### Claim 30 (depends on 25)

The antibody of claim 25, wherein the heavy chain has an amino acid sequence of SEQ ID NO:180 with or without C-terminal lysine and the light chain has an amino acid sequence of SEQ ID NO:181.

### Claim 31 (depends on 19)

The antibody of claim 19 having at least one mutation in the constant region.

### Claim 32 (depends on 31)

The antibody of claim 31, wherein the mutation reduces complement fixation or activation by the constant region or reduces binding to a Fcγ receptor relative to the natural human heavy chain constant region.

### Claim 33 (depends on 32)

The antibody of claim 32 having a mutation at one or more of positions 241, 264, 265, 270, 296, 297, 318, 320, 322, 329 and 331 by EU numbering or having alanine at positions 318, 320 and 322.

### Claim at position 31

34-36. (canceled)

### Claim 37 (depends on 1)

The antibody of claim 1, wherein the antibody is conjugated to a therapeutic, cytotoxic, cytostatic, neurotrophic, or neuroprotective agent.

### Claim 38 (depends on 1)

A pharmaceutical composition comprising an antibody as defined in claim 1 and a pharmaceutically-acceptable carrier.

### Claim 39 (depends on 1)

A nucleic acid encoding the heavy chain and/or light chain of an antibody as described in claim 1.

### Claim 40 (depends on 39)

The nucleic acid of claim 39, wherein the heavy chain is encoded by a sequence comprising SEQ ID NO:182 and the light chain is encoded by a sequence comprising SEQ ID NO:183.

### Claim 41 (depends on 40)

A method of producing an antibody, the method comprising:
(a) culturing cells transformed with the nucleic acid of claim 40, so that the cells secrete the antibody; and
(b) purifying the antibody from cell culture media.

### Claim 42 (depends on 40)

A method of producing a cell line producing an antibody, the method comprising:
(a) introducing a vector encoding the nucleic acid of claim 40 and a selectable marker into cells;
(b) propagating the cells under conditions to select for cells having increased copy number of the vector;
(c) isolating single cells from the selected cells; and
(d) banking cells cloned from a single cell selected based on yield of antibody.

### Claim 43 (depends on 1)

A method of producing an antibody, the method comprising:
(a) culturing cells transformed with nucleic acids encoding the heavy and light chains of the antibody of claim 1, so that the cells secrete the antibody; and
(b) purifying the antibody from cell culture media.

### Claim 44 (depends on 1)

A method of producing a cell line producing an antibody, the method comprising:
(a) introducing a vector encoding heavy and light chains of the antibody of claim 1 and a selectable marker into cells;
(b) propagating the cells under conditions to select for cells having increased copy number of the vector;
(c) isolating single cells from the selected cells; and
(d) banking cells cloned from a single cell selected based on yield of antibody.

### Claim 45 (depends on 1)

A method of inhibiting or reducing aggregation of tau in a subject having or at risk of developing a tau-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby inhibiting or reducing aggregation of tau in the subject.

### Claim 46 (depends on 45)

The method of claim 45, wherein the antibody is a humanized version of an antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO:7 and a light chain variable region having an amino acid sequence comprising SEQ ID NO:11.

### Claim 47 (depends on 1)

A method of treating or effecting prophylaxis of a tau-related disease in a subject, comprising administering an effective regime of an antibody as defined by claim 1 and thereby treating or effecting prophylaxis of the disease.

### Claim at position 43

48-50. (canceled)

### Claim 51 (depends on 1)

A method of reducing aberrant transmission of tau, inducing phagocytosis of tau, inhibiting tau deposition or aggregation, or inhibiting formation of tau tangles in a subject, comprising administering to the subject an effective regime of an antibody as defined in claim 1 and thereby reducing transmission of tau, inducing phagocytosis of tau, inhibiting tau aggregation or deposition, or inhibiting formation of tau tangles in the subject.

### Claim at position 45

52-56. (canceled)

### Claim 57 (depends on 45)

The method of claim 45, wherein the antibody is administered by intravenous injection into the body of the subject.

### Claim at position 47

58-61. (canceled)

### Claim 62 (depends on 1)

A method of measuring efficacy of treatment in a subject being treated for a disease associated with tau aggregation or deposition, comprising
(a) measuring a first level of tau protein deposits in the subject prior to treatment by administering to a subject an antibody defined by claim 1, and detecting a first amount of the antibody bound to tau in the subject,
(b) administering the treatment to the subject,
(c) measuring a second level of tau protein deposits in the subject after treatment by administering to a subject the antibody, and detecting the antibody bound to tau in the subject,
wherein a decrease in the level of tau protein deposits indicates a positive response to treatment.

### Claim 63 (depends on 1)

A method of measuring efficacy of treatment in a subject being treated for a disease associated with tau aggregation or deposition, comprising
(a) measuring a first level of tau protein deposits in the subject prior to treatment by administering to a subject an antibody defined by claim 1, and detecting a first amount of antibody bound to tau in the subject,
(b) administering the treatment to the subject,
(c) measuring a second level of tau protein deposits in the subject after treatment by administering to a subject the antibody, and detecting a second amount of antibody bound to tau in the subject,
wherein no change in the level of tau protein deposits or a small increase in tau protein deposits indicates a positive response to treatment.

### Claim 64

A method of producing an antibody that specifically binds to human tau at an epitope within a motif of the formula KXXSXXNX(K/H)H (SEQ ID NO:191) or KIGSLDNITH (SEQ ID NO:194) comprising immunizing an animal with human tau or a fragment thereof to produce antibodies and screening for an antibody of the produced antibodies that specifically binds within the motif.

### Claim at position 51

65-66. (canceled)

### Claim 67 (depends on 64)

The method of claim 64, wherein the animal is immunized with 383 amino acid human tau (4R0N).

### Claim 68 (depends on 67)

The method of claim 67, wherein the human tau contains a P301S mutation.

### Claim 69

(canceled)

### Claim 70 (depends on 64)

The method of claim 64, wherein the screening determines specific binding between the antibodies and one or more peptides of up to 15 amino acids comprising KIGSTENLKH (SEQ ID NO:188), KCGSKDNIKH (SEQ ID NO:192), KCGSLGNIHH (SEQ ID NO: 193) respectively or any other consensus motif represented by KXXSXXNX(K/H)H (SEQ ID NO:191).

### Claim 71

(canceled)

### Claim 72 (depends on 64)

The method of claim 64, wherein the animal is immunized with a tau fragment of up to 15 amino acids comprising KXXSXXNX(K/H)H (SEQ ID NO:191), linked to a carrier.

### Claim 73 (depends on 72)

The method of claim 72, wherein the peptide is KIGSTENLKH (SEQ ID NO:188) or KCGSKDNIKH (SEQ ID NO:192) or KCGSLGNIHH (SEQ ID NO: 193).

### Claim 74 (depends on 47)

The method of claim 47, wherein the antibody is administered by intravenous injection into the body of the subject.

### Claim 75 (depends on 51)

The method of claim 51, wherein the antibody is administered by intravenous injection into the body of the subject.
